MetaCap

Corvus Pharmaceuticals (CRVS) vs Pharming Group N.V. (PHAR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Corvus Pharmaceuticals (CRVS) has outperformed Pharming Group N.V. (PHAR) over the past year, gaining 12.8% versus a loss of 29.0%. Over five years, CRVS leads with a +183.6% price change compared with +39.0% for PHAR. Pharming Group N.V. is the larger company by market cap ($816.8 million vs $815.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRVS+12.84%PHAR-29.03%
+210%+77%-56%
Nov 21, 20251 yearNov 20, 2026
CRVS+176.29%PHAR+33.87%
+652%+268%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRVS versus PHAR key metrics
MetricCRVSPHAR
Share price$9.67$11.54
Market cap$815.69M$816.78M
1-day change-3.40%-5.10%
YTD return+25.58%-34.69%
1-year return+12.84%-29.03%
5-year return+183.58%+39.04%
P/E ratio (TTM)—36.06
Forward P/E—64.11
EPS (TTM)$-0.72$0.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$376.13M
Revenue growth (YoY)—+26.56%
Net income (latest FY)$-15.28M$2.85M
Gross margin—87.90%
Operating margin—6.87%
Net margin—0.76%
52-week high$26.95$21.34
52-week low$6.39$9.11
Distance from 52-week high-64.12%-45.92%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+225.75%+209.36%
Average volume1.05M21.33K
Shares outstanding84.35M70.78M
Employees37407
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CRVS has outperformed PHAR by 41.9 percentage points over the past year.

About Corvus Pharmaceuticals

CRVS stock →

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees

About Pharming Group N.V.

PHAR stock →

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees

CRVS vs PHAR FAQ

Which is bigger, Corvus Pharmaceuticals or Pharming Group N.V.?

Pharming Group N.V. (PHAR) is larger, with a market capitalization of $816.78M compared with $815.69M for Corvus Pharmaceuticals (CRVS).

Which stock has performed better over the past year, CRVS or PHAR?

CRVS returned +12.84% over the past 12 months, compared with -29.03% for PHAR (price return, excluding dividends). Past performance does not predict future results.

Are Corvus Pharmaceuticals and Pharming Group N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons